Market Chatter: Eli Lilly, Pfizer Among Drugmakers Eyeing a Spot in Chinese Commercial Health Insurance Catalog

MT Newswires Live

2025/08/12

Eli Lilly (LLY), Pfizer (PFE), Novo Nordisk (NVO), and Biogen (BIIB) are among a number of Western pharmaceutical companies that have applied for their drugs and treatments to be included in China's new catalog of commercial health insurance, Bloomberg reported Tuesday.

The list includes Alzheimer's therapies from Eli Lilly, cancer treatments from Bristol-Myers Squibb (BMY), and an oral diabetes drug from Novo Nordisk. Other companies that featured in the list included Gilead Sciences (GILD), Johnson & Johnson (JNJ), and AstraZeneca (AZN), the report said.

A total of 121 drugs passed the preliminary evaluation, and a final decision is expected by October or November, the report added.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2558464506"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2558464506\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2558464506?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-12 18:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2558464506","market":"sg","top_or_hot":-1,"title":"Market Chatter: Eli Lilly, Pfizer Among Drugmakers Eyeing a Spot in Chinese Commercial Health Insurance Catalog","media":"MT Newswires Live","content":"<html><body><p> Eli Lilly (LLY), Pfizer (PFE), <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> (NVO), and Biogen (BIIB) are among a number of Western pharmaceutical companies that have applied for their drugs and treatments to be included in China's new catalog of commercial health insurance, Bloomberg reported Tuesday.</p><p>The list includes Alzheimer's therapies from Eli Lilly, cancer treatments from <a href=\"https://laohu8.com/S/BMYMP\">Bristol-Myers Squibb</a> (BMY), and an oral diabetes drug from Novo Nordisk. Other companies that featured in the list included <a href=\"https://laohu8.com/S/GILD\">Gilead</a> Sciences (GILD), Johnson &amp; Johnson (JNJ), and AstraZeneca (AZN), the report said.</p><p>A total of 121 drugs passed the preliminary evaluation, and a final decision is expected by October or November, the report added.</p><p>(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Market Chatter: Eli Lilly, Pfizer Among Drugmakers Eyeing a Spot in Chinese Commercial Health Insurance Catalog</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMarket Chatter: Eli Lilly, Pfizer Among Drugmakers Eyeing a Spot in Chinese Commercial Health Insurance Catalog\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-08-12 18:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Eli Lilly (LLY), Pfizer (PFE), <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> (NVO), and Biogen (BIIB) are among a number of Western pharmaceutical companies that have applied for their drugs and treatments to be included in China's new catalog of commercial health insurance, Bloomberg reported Tuesday.</p><p>The list includes Alzheimer's therapies from Eli Lilly, cancer treatments from <a href=\"https://laohu8.com/S/BMYMP\">Bristol-Myers Squibb</a> (BMY), and an oral diabetes drug from Novo Nordisk. Other companies that featured in the list included <a href=\"https://laohu8.com/S/GILD\">Gilead</a> Sciences (GILD), Johnson &amp; Johnson (JNJ), and AstraZeneca (AZN), the report said.</p><p>A total of 121 drugs passed the preliminary evaluation, and a final decision is expected by October or November, the report added.</p><p>(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1868836591.USD","symbol_name":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2558464506","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2558464506","pubTimestamp":1754995282,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Eli Lilly , Pfizer , Novo Nordisk , and Biogen  are among a number of Western pharmaceutical companies that have applied for their drugs and treatments to be included in China's new catalog of commercial health insurance, Bloomberg reported Tuesday.The list includes Alzheimer's therapies from Eli Lilly, cancer treatments from Bristol-Myers Squibb , and an oral diabetes drug from Novo Nordisk. Other companies that featured in the list included Gilead Sciences , Johnson & Johnson , and AstraZeneca , the report said.A total of 121 drugs passed the preliminary evaluation, and a final decision is expected by October or November, the report added.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","IE00B42XCP33.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) INC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","BMY":"施贵宝","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","BK4566":"资本集团","JNJ":"强生","PFE":"辉瑞","GILD":"吉利德科学","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU0234572021.USD":"高盛美国核心股票组合Acc","LU1032955483.USD":"NORDEA 1 STABLE RETURN \"HB\" (USDHDG) ACC","LU2129689431.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) ACC","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU2360106947.USD":"BGF NUTRITION \"A4\" (USD) INC","NVO.AU":"NOVO RESOURCES CORP-CDI","AZN":"阿斯利康","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU2430703178.SGD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (SGDHDG) INC","LU2430703251.USD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4\" (USD) INC","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","LLY":"礼来","SG9999017495.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"B\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0203201768.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"AX\" (USD) INC","BIIB":"渤健公司","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","PFE.AU":"PANTERA MINERALS LTD","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","SG9999014898.SGD":"United Global Quality Growth Fund Dis SGD","LU1674673691.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (USD) INC","IE00BJLML261.HKD":"HSBC GLOBAL EQUITY INDEX \"HCH\" (HKD) ACC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU1674673428.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AC\" (USD) ACC","LU0238689110.USD":"贝莱德环球动力股票基金","LU0109391861.USD":"富兰克林美国机遇基金A Acc","NVO":"诺和诺德","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","SGXZ99366536.SGD":"United Global Innovation A Acc SGD-H"},"translate_title":"市场热议：礼来、辉瑞等制药商觊觎中国商业医保目录","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":1,"PFE.AU":1,"NVO":0.9,"AZN":0.9,"BIIB":0.9,"BMY":0.9,"PFE":1,"GILD":0.9,"JNJ":0.9,"NVO.AU":1},"content_text":"Eli Lilly (LLY), Pfizer (PFE), Novo Nordisk (NVO), and Biogen (BIIB) are among a number of Western pharmaceutical companies that have applied for their drugs and treatments to be included in China's new catalog of commercial health insurance, Bloomberg reported Tuesday.The list includes Alzheimer's therapies from Eli Lilly, cancer treatments from Bristol-Myers Squibb (BMY), and an oral diabetes drug from Novo Nordisk. Other companies that featured in the list included Gilead Sciences (GILD), Johnson & Johnson (JNJ), and AstraZeneca (AZN), the report said.A total of 121 drugs passed the preliminary evaluation, and a final decision is expected by October or November, the report added.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}